Merck RotaTeq Observational Study For Intussusception Will Enroll 28,000
Executive Summary
A post-marketing observational study for Merck's RotaTeq will enroll 28,000 patients to track reports of intussusception and other potential adverse events, the company told FDA's Vaccines & Related Biological Products Advisory Committee at its Dec. 14 meeting
You may also be interested in...
GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support
With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan
GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support
With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan
Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads
Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq